Divi's Lab hits 52-week low; stock tanks 17% intra-day
Disclaimer: Information presented on this site is a guide only. It may not necessarily be correct and is not intended to be taken as financial advice nor has it been prepared with regard to the individual investment needs and objectives or financial situation of any particular person. Stock quotes are believed to be accurate and correctly dated, but www.stockmarketindian.com does not warrant or guarantee their accuracy or date.
www.stockmarketindian.com takes no responsibility for any investment decisions based on recommendations provided on website.
Financial contents like Technical charts, historical charts and quotes are taken from NSE and Yahoo sites.
Note - All quotes are delayed by 15 minutes and unless specified.
Google Adsense Ads are posted on every page of the website so visitors clicking on Ads and going to those links and carrying any financial deal is not at all related to www.stockmarketindian.com and any financial deal should be done on their own sole responsibility.
Please read our Disclaimer page before using any material or advice given at www.stockmarketindian.com
Your place to Learn and Earn
updated on 24 Dec 2016
Divis Laboratories hits 52-week low of Rs 918, down 17% on the BSE in intra-day trade on back of heavy volumes.
At 01:52 pm; the stock was down 16% at Rs 927 on the BSE as compared to 0.44% rise in the S&P BSE Sensex. The trading volumes on the counter jumped more than 10-fold with a combined 3.97 million shares changed hands on the BSE and NSE so far.
On December 7, 2016, the US Food and Drug Administration (USFDA) had issued form 483 with five observations against Divi's Laboratories' unit at Chippada Village in Visakhapatnam of Andhra Pradesh. The USFDA inspected the company’s unit from November 29, 2016 to December 6, 2016.
Form 483 relates to certain critical observations issued to a company at the end of an inspection if there were any violations of the Food Drug and Cosmetic Act and other related acts of the US Government.
Divi's manufactures active pharmaceutical ingredients (APIs) and intermediates for generics among others at this plant.